Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
A Tier-1 integrated pharma group operating a backward-integrated manufacturing footprint — a Chapter 29 API plant at Kurkumbh in Maharashtra manufacturing antibiotic APIs, and a Chapter 30 formulation plant at Verna in Goa converting those APIs into finished dosage forms — transfers approximately Rs 350 crore of intra-group Chapter 29 APIs from the API plant to the formulation plant every FY. Where either unit enjoys a tax holiday under Section 80-IE, Section 80-IC, Section 10AA or Section 115BAB, the aggregate crosses the Rs 20 crore Section 92BA previous-year threshold and the transaction is a specified domestic transaction requiring Rule 10D contemporaneous documentation, Section 92C arm's length price determination under one of the six prescribed methods (typically CUP for commodity APIs and TNMM for specialty APIs), and Form 3CEB filing with the annual return by 31 October of the assessment year. In parallel, every intra-group inter-state API dispatch is a paragraph 2 Schedule I supply under the CGST Act 2017 attracting IGST at 5 percent under HSN Chapter 29 heading 2941, valued under Section 15(4) read with Rule 28 (with the full-ITC safe harbour in the second proviso), and generating an ITC availment at the formulation plant that must reconcile to the API plant's outward supply register invoice-by-invoice.
Build a per-molecule per-tax-period intra-group transfer workbook keyed on the API plant GSTIN and the formulation plant GSTIN. Extract the API plant's outward supply register from GSTR-1 into the dispatch register — captured by HSN sub-heading (2941 antibiotics, 2933 heterocyclic compounds, 2934 nucleic acids), quantity in kilograms, and invoice value at the intra-group transfer price. Extract the formulation plant's ITC register from GSTR-2B into the receipt-side register — matched invoice-by-invoice on GSTIN plus invoice number plus date plus value plus tax. Reconcile the two sides for the tax period so that every dispatch from the API plant has a matching receipt at the formulation plant within the ITC-availment window. On the income-tax side, extract the annual intra-group transfer volume by HSN sub-heading and by molecule from the dispatch register. For each molecule, apply the transfer pricing methodology selected in the Rule 10D documentation — CUP where external market price is verifiable, TNMM where specialty. Compute the arm's length range under Rule 10CA. Compare the intra-group transfer price against the arm's length range. Prepare the Rule 10D contemporaneous documentation with the FAR analysis, the benchmarking study and the arm's length range test. Feed the SDT particulars into Form 3CEB Part C. File Form 3CEB with the return by 31 October of the assessment year. On the GST side, verify that the recipient formulation plant is eligible for full ITC (the standard case post the 22 September 2025 rate reset where downstream Chapter 30 output attracts 5 percent GST), which triggers the second-proviso-to-Rule-28 safe harbour and accepts the invoice value as the open market value.
API plant master and formulation plant master with GSTINs, states, tax-holiday status (Section 80-IE, Section 80-IC, Section 10AA, Section 115BAB flag), and HSN Chapter 29 or Chapter 30 assignment; molecule master keyed by name and HSN sub-heading (2941, 2933, 2934, 2939) with production cost benchmark and industry external market price reference where CUP applies; intra-group invoice register per FY with molecule-wise volume in kilograms and rupees; Section 92BA SDT threshold monitor cumulating aggregate SDT value against the Rs 20 crore previous-year threshold; Rule 10D documentation register per molecule per FY holding the FAR analysis, transfer pricing methodology, benchmarking study, arm's length range under Rule 10CA and comparability adjustments; Form 3CEB Part C feed with per-SDT particulars ready for accountant certification; GSTR-1 outward supply extract from the API plant GSTIN and GSTR-2B inward ITC extract from the formulation plant GSTIN with dispatch-to-receipt matching for the tax period; ITC continuity register from the API plant dispatch to the formulation plant availment; Section 15(4) read with Rule 28 valuation register with full-ITC safe harbour flag per invoice; year-end group-consolidation elimination worksheet for the intra-group profit-in-inventory at the formulation plant balance sheet date.
A year-end backward-integration transfer pricing pack: per-molecule per-FY intra-group transfer volume and value, the Section 92BA SDT threshold cumulation showing whether the Rs 20 crore aggregate is crossed, the Rule 10D contemporaneous documentation set (ownership structure, FAR analysis, transfer pricing methodology, benchmarking study, arm's length range under Rule 10CA), the Form 3CEB Part C draft ready for chartered-accountant certification, the accountant-certified Form 3CEB filed with the return by 31 October of the assessment year, and the parallel GST-side reconciliation showing the intra-group inter-state IGST 5 percent dispatch register from the API plant GSTIN matched invoice-by-invoice to the ITC availment register at the formulation plant GSTIN with the full-ITC safe-harbour flag confirming the invoice value is deemed the open market value under the second proviso to Rule 28. A rolling monthly view surfaces the SDT threshold cumulation early so the Rule 10D documentation build starts before the year-end scramble. A year-end reconciliation between the Section 92C arm's length price and the GST Rule 28 invoice value confirms the two regimes carry the same number, closing the two-track exposure.
A Tier-1 integrated pharma group running a backward-integrated Indian manufacturing footprint — a Chapter 29 API plant at Kurkumbh in Maharashtra manufacturing antibiotic active pharmaceutical ingredients, and a Chapter 30 formulation plant at Verna in Goa converting those APIs into finished dosage forms for domestic distribution and export — closes its books for FY 2026-27 with aggregate intra-group API transfers approaching Rs 350 crore for the year. Every kilogram of Cefixime (HSN 2941.90) dispatched from Kurkumbh to Verna is a related-party transaction on the income-tax side, a distinct-persons inter-state supply on the GST side, and a group-consolidation elimination on the accounting side. Where at least one of the two units enjoys a tax holiday under Section 80-IE, Section 80-IC, Section 10AA or Section 115BAB and the aggregate value of such intra-group specified domestic transactions crosses the Rs 20 crore threshold in Section 92BA of the Income-tax Act, Rule 10D contemporaneous documentation is triggered, the arm’s length price must be established under one of the six prescribed methods (CUP for commodity APIs, TNMM for specialty), and the Form 3CEB accountant’s report must be filed with the annual return by 31 October of the assessment year. This is backward integration API manufacturing transfer pricing pharma Section 92BA at operating scale — a two-regime reconciliation surface spanning income tax and GST that must resolve to the same intra-group transfer price on both sides.
Quick reference
| Aspect | Detail |
|---|---|
| Income-tax provision | Section 92BA, Income-tax Act 1961 (retained in the Income-tax Act 2025 codification) |
| SDT trigger threshold | Aggregate SDT exceeds Rs 20 crore in the previous year |
| Tax-holiday hooks | Section 80-IE (north-eastern and hill states, Sikkim); Section 80-IC (Baddi, Uttarakhand — mostly sunset for new units); Section 10AA (SEZ); Section 115BAB (new manufacturing companies) |
| Documentation rule | Rule 10D, Income-tax Rules 1962 (contemporaneous documentation) |
| Retention period | 8 years from the end of the relevant AY |
| Arm’s length methods | CUP, RPM, CPM, PSM, TNMM, Other Method (Rule 10B); range under Rule 10CA |
| Accountant’s report | Form 3CEB under Section 92E; due 31 October of AY |
| Master file rule | Rule 10DA (Form 3CEAA) — applies only for international groups above thresholds |
| GST valuation | Section 15(4) CGST Act 2017 read with Rule 28 CGST Rules 2017 |
| GST safe harbour | Second proviso to Rule 28 — full-ITC recipient: invoice value deemed OMV |
| Schedule I trigger | Paragraph 2 — distinct-persons supply deemed even without consideration |
| API HSN | Chapter 29 heading 2941 (antibiotics); 2933 (heterocyclic compounds); 2934 (nucleic acids); 2939 (alkaloids) |
| API GST rate | 5 percent under standing rate notification |
| Penalty for non-filing 3CEB | Rs 1 lakh under Section 271BA |
| Penalty for non-maintenance of documentation | 2 percent of SDT value under Section 271AA |
The reconciliation in one paragraph
A backward-integrated pharma group with an intra-group API plant and formulation plant sitting under separate state GSTINs runs three parallel books on every kilogram of API dispatched across the group boundary. On the income-tax side, Section 92BA of the Income-tax Act defines the specified domestic transaction; Rule 10D of the Income-tax Rules 1962 prescribes the contemporaneous documentation; Section 92C read with Rule 10B lists the six arm’s length pricing methods (CUP, RPM, CPM, PSM, TNMM, Other); Rule 10CA prescribes the arm’s length range test; Form 3CEB under Section 92E is the accountant’s report filed with the return by 31 October of the assessment year. On the GST side, paragraph 2 of Schedule I of the CGST Act 2017 deems the intra-group inter-state supply taxable even without consideration; Section 15(4) read with Rule 28 of the CGST Rules 2017 governs the value of supply between related persons, with the second-proviso safe harbour accepting the invoice value as the open market value where the recipient is eligible for full input tax credit. On the accounting side, Ind AS 24 mandates related-party disclosure in the group’s consolidated financial statements, and the intra-group profit-in-inventory at the formulation plant’s balance sheet date must be eliminated on group consolidation. The reconciliation discipline is a per-molecule per-tax-period workbook that harmonises the arm’s length price on the income-tax side, the invoice value on the GST side, and the elimination entry on the accounting side — so all three regimes carry the same underlying number and the reconciliation between them is a one-line linkage rather than a three-track exposure.
What the scenario looks like in India
Backward integration is the dominant Indian pharma manufacturing model. Tier-1 integrated formulators run captive Chapter 29 API capacity that feeds their downstream Chapter 30 formulation plants — the pattern was built through the 1990s and 2000s under the process-patent regime and remains the industry’s structural advantage even after the transition to product-patent protection in 2005. Illustrative Tier-1 groups running backward-integrated API-plus-formulation footprints at the scale relevant to this reconciliation include Sun Pharmaceutical Industries (formulation plants at Halol in Gujarat, Baddi in Himachal Pradesh, and Sikkim); Cipla (API capacity at Kurkumbh in Maharashtra feeding formulation plants at Verna in Goa, Baddi and Sikkim); Dr Reddy’s Laboratories (API capacity at Bollaram and Bachupally in the Hyderabad belt feeding formulation plants at Hyderabad, Vishakhapatnam and Baddi); Aurobindo Pharma (API and formulation capacity in the Hyderabad belt with additional units at Vishakhapatnam); Lupin (API capacity at Ankleshwar and Vadodara in Gujarat feeding formulation plants at Ahmedabad, Baddi and Sikkim); Zydus Lifesciences (API capacity at Ankleshwar feeding formulation plants at Ahmedabad, Halol, Baddi and Sikkim); Torrent Pharmaceuticals; Alkem Laboratories; Glenmark Pharmaceuticals; and Cadila Pharmaceuticals. Tier-2 API-focused players — Divi’s Laboratories, Neuland Laboratories, Laurus Labs at Vishakhapatnam, Granules India — run standalone Chapter 29 API plants that either supply their group formulation units or sell to third-party formulators on a CDMO or CRAMS basis. Piramal Pharma, Ipca Laboratories and Ajanta Pharma operate integrated API-plus-formulation footprints of comparable scale.
For the reconciliation this article walks through, the reference persona is an illustrative Tier-1 group operating a Chapter 29 API plant at Kurkumbh in Maharashtra manufacturing antibiotic APIs (Cefixime, Amoxicillin, Ciprofloxacin, Azithromycin) and a Chapter 30 formulation plant at Verna in Goa converting those APIs into finished-dosage-form tablets, capsules and injectables. Aggregate intra-group Chapter 29 API transfers from Kurkumbh to Verna run at approximately Rs 350 crore per FY. The formulation plant at Verna also supplies a share of its output to export markets under Section 10AA-eligible SEZ operations at a related group unit or under an EOU arrangement — bringing at least one leg of the group inside the Section 92BA tax-holiday-unit trigger. The intra-group SDT is well above the Rs 20 crore aggregate previous-year threshold, and Rule 10D contemporaneous documentation, Section 92C arm’s length benchmarking, and Form 3CEB filing under Section 92E are all triggered.
The regulatory overlay — Section 92BA, Rule 10D, Section 92C, Section 15 CGST, Rule 28
Six anchors govern the backward-integration transfer pricing reconciliation. Four sit on the income-tax side and two on the GST side; all six must resolve to the same intra-group transfer price for the workbook to close.
Section 92BA of the Income-tax Act 1961 (retained in the Income-tax Act 2025 codification) defines the specified domestic transaction. The current scope, post the Finance Act 2017 deletion of clause (i), covers transactions in Section 80A (inter-unit transfers at tax-holiday units), Section 80-IA(8) (transfers of goods or services with a tax-holiday unit), Section 80-IA(10) (business between the assessee and an inter-connected person at other-than-market prices), Section 10AA (SEZ units) and Section 115BAB(6) (new manufacturing companies at the concessional 15 percent tax rate). The trigger arises for a backward-integrated pharma group where at least one of the API plant or the formulation plant enjoys a tax holiday. Section 80-IE covers north-eastern and hill states (including Sikkim). Section 80-IC covered Baddi in Himachal Pradesh, Uttarakhand and the north-eastern states — mostly sunset for new units, but existing units with claim periods still open remain within scope. Section 10AA covers SEZ units. Section 115BAB applies to new manufacturing companies that opt for the 15 percent concessional rate. Where either unit sits within one of these hooks AND the aggregate SDT value in the previous year exceeds Rs 20 crore, the SDT provisions apply.
Rule 10D of the Income-tax Rules 1962 prescribes the contemporaneous documentation set — ownership structure, group profile, description of the SDT with each associated enterprise, FAR analysis (functions performed, risks assumed, assets employed), transfer pricing methodology selection with reasons, arm’s length range benchmarking study drawn from external comparables, and any other relevant information. The documentation must be contemporaneous with the transaction and preserved for eight years from the end of the relevant assessment year. This is the local file. The master file under Rule 10DA (Form 3CEAA) is a separate requirement that applies only for constituents of an international group above specified consolidated-revenue and international-transaction thresholds; for a pure domestic-SDT-only group, only Rule 10D applies.
Section 92C of the Income-tax Act read with Rule 10B prescribes the six arm’s length pricing methods — Comparable Uncontrolled Price (CUP), Resale Price Method (RPM), Cost Plus Method (CPM), Profit Split Method (PSM), Transactional Net Margin Method (TNMM), and Other Method (as prescribed by the Board). Rule 10CA prescribes the arm’s length range mechanics — the interquartile-range test where six or more comparables are available, the arithmetic-mean plus-or-minus-three-percent-tolerance test in other cases. For an intra-group Chapter 29 API transfer, CUP is the preferred method where an external market price for the same molecule at the same volume tier and delivery terms is verifiable (industry price bulletins for commodity antibiotic APIs; ICEGATE Bill of Entry data for imported comparables). Where the API is specialty or proprietary and external comparables are limited, TNMM is the pragmatic choice — comparing the tested-party’s net cost-plus margin against a set of comparable independent Indian API manufacturers screened by industry code, turnover band, and functional profile from Prowess or Capitaline databases.
Section 15(4) of the CGST Act 2017 read with Rule 28 of the CGST Rules 2017 governs the GST-side value of supply between related persons. Rule 28(a) prescribes open market value as the primary anchor; Rule 28(b) prescribes value of like kind and quality supplies where OMV is unavailable; Rules 30 and 31 provide fallback bases. The critical safe harbour sits in the second proviso to Rule 28: where the recipient is eligible for full input tax credit, the value declared in the invoice by the supplier is deemed to be the open market value. Paragraph 2 of Schedule I of the CGST Act 2017 deems the intra-group inter-state supply taxable even without monetary consideration. The intra-group Chapter 29 API dispatch from Kurkumbh to Verna therefore attracts IGST at 5 percent on the Rule 28 value; the formulation plant avails full ITC (its downstream Chapter 30 output attracts 5 percent GST post the 22 September 2025 rate reset covered in the Wave A cornerstone on the 56th GST Council pharma rate transition); and the safe harbour accepts the invoice value declared by Kurkumbh as the open market value without a separate Rule 28(a) benchmarking exercise on the GST side.
Form 3CEB under Section 92E is the accountant’s report filed electronically with the return of income by 31 October of the assessment year, containing Part C particulars of each SDT — description, quantum, method, arm’s length price computation, comparability adjustments. Failure to file attracts a Rs 1 lakh penalty under Section 271BA; failure to maintain Rule 10D documentation attracts a 2 percent penalty on SDT value under Section 271AA; adoption of a non-arm’s-length price attracts an income adjustment plus penalty under Section 270A.
A worked example — an illustrative Kurkumbh-to-Verna Cefixime intra-group transfer
Illustrative — the figures below represent the operating pattern of a Tier-1 backward-integrated Indian pharma group with a Maharashtra API plant and a Goa formulation plant. Public disclosures do not reveal per-molecule intra-group transfer prices, cost bases or arm’s length benchmarks in the granularity below; cross-verify against your own group’s SDT register, cost accounting records, and external comparable data before action.
The reference persona’s Kurkumbh API plant manufactures Cefixime (HSN 2941.90 — Other antibiotics), a third-generation cephalosporin antibiotic API, at a full manufacturing cost of Rs 4,800 per kilogram — comprising raw material at Rs 2,900 (7-ACA intermediate plus reagents and solvents), direct labour at Rs 400, plant overhead at Rs 900 (utilities, depreciation, maintenance, quality control), and packaging plus quality-release cost of Rs 600. The intra-group transfer price to the Verna formulation plant is set at Rs 5,200 per kilogram — a cost-plus margin of approximately 8.3 percent over the full manufacturing cost. Aggregate volume for FY 2026-27 is 6,700 kilograms, giving an aggregate intra-group transfer value of Rs 3.48 crore for Cefixime alone. Adding the parallel intra-group transfers of Amoxicillin, Ciprofloxacin, Azithromycin and other antibiotic APIs to Verna, the aggregate intra-group SDT for the year sits at approximately Rs 350 crore — well above the Rs 20 crore Section 92BA previous-year threshold.
On the income-tax side, the group’s transfer pricing team runs a CUP benchmarking for Cefixime using industry price-bulletin data for the same molecule at the same volume tier and delivery terms. External CUP prices in FY 2026-27 range from Rs 4,900 to Rs 5,600 per kilogram, with an interquartile range under Rule 10CA of Rs 5,050 to Rs 5,450. The intra-group transfer price of Rs 5,200 sits inside the interquartile range and is accepted as arm’s length. The Rule 10D contemporaneous documentation records the CUP benchmarking, the source of the comparables (published bulletins and ICEGATE Bill of Entry data), the FAR analysis (Kurkumbh performs API manufacture and quality release; Verna performs formulation and packaging; both bear market and inventory risks proportionate to functions), and the arm’s length range computation. Form 3CEB Part C captures the SDT particulars for filing by 31 October 2027.
On the GST side, Kurkumbh dispatches the 6,700 kilograms across the year in periodic tax invoices to Verna at Rs 5,200 per kilogram plus IGST at 5 percent — that is, Rs 5,460 per kilogram invoice value. Verna avails full ITC on receipt because its downstream Chapter 30 formulation output attracts 5 percent GST. The second proviso to Rule 28 kicks in and deems the invoice value the open market value; no separate GST-side benchmarking is required. The intra-group transfer price on the income-tax side (Rs 5,200) matches the invoice value on the GST side (Rs 5,200) — the two regimes are harmonised, and the reconciliation between them is a one-line linkage rather than a two-track exposure.
On the accounting side, the intra-group profit at Rs 400 per kilogram (Rs 5,200 transfer price minus Rs 4,800 cost), totalling Rs 26.8 lakh for Cefixime alone across the year’s volume, must be eliminated on group consolidation to the extent it remains in Verna’s closing inventory at the balance sheet date. If Verna’s closing inventory of unconsumed Cefixime is 500 kilograms, the elimination entry against consolidated inventory and consolidated gross profit is Rs 2 lakh (500 kilograms multiplied by Rs 400 per kilogram intra-group profit).
Common reconciliation breakages
-
Section 80-IE / 80-IC / 10AA hook mis-flagged at plant master. The Section 92BA trigger depends on at least one unit enjoying a tax holiday. Groups that historically claimed Section 80-IC or Section 80-IE at a Baddi or Sikkim formulation plant but let the deduction sunset without updating the plant master’s SDT-in-scope flag mis-scope the intra-group transfer — either over-documenting a non-SDT relationship or, more dangerously, under-documenting where a Section 115BAB election or a fresh Section 10AA SEZ unit brought a leg back into scope. Reconciliation discipline: the plant master’s tax-holiday status is refreshed every FY against the claim-period sunset dates, and the SDT-scope flag drives the Rule 10D documentation trigger.
-
CUP benchmarking uses non-comparable volume tier or delivery terms. For commodity antibiotic APIs, CUP looks defensible only when the external comparable is at the same volume tier (bulk drum quantities), the same delivery terms (INR ex-plant vs USD CIF port of import), the same quality grade (pharma-grade vs technical-grade), and the same regulatory status (USFDA-approved vs domestic-only). Groups that pull an external price from a spot-market bulletin without normalising for volume tier or delivery terms produce a CUP range that a Transfer Pricing Officer disallows at scrutiny. Discipline: the Rule 10D documentation records the comparability adjustments made to normalise each external CUP data point to the tested-party terms.
-
TNMM comparable set drawn without industry-code screening. For specialty APIs where CUP is unavailable and TNMM is used, the comparable set must be drawn from independent Indian API manufacturers screened by industry code (NIC codes for pharma manufacturing including 21001 for bulk drugs, 21002 for pharmaceutical formulations, 21003 for pharmaceutical machinery — with the tested party being a bulk-drug manufacturer, only 21001 should feed the pool). Groups that fold formulation manufacturers (21002) into the comparable set for an API tested party produce a TNMM margin range that mis-scales the arm’s length test. Discipline: the comparable-set screening criteria are recorded in the Rule 10D documentation with the accept/reject decision noted for each candidate.
-
GST invoice value diverges from the income-tax arm’s length price. The full-ITC safe harbour under the second proviso to Rule 28 holds only if the invoice value is what the group intends to defend on both regimes. Groups that set the GST invoice value at cost (Rs 4,800) but the income-tax arm’s length price at Rs 5,200 create a two-track exposure — the Transfer Pricing Officer disputes the income-tax price and the GST officer disputes the GST value, and the group has to defend two different numbers with two different narratives. Discipline: the GST invoice value and the income-tax arm’s length price are set as the same number at intra-group invoice generation, and the workbook records the linkage.
-
Group-consolidation elimination entry missed on closing inventory. The intra-group profit component in the formulation plant’s closing inventory at the balance sheet date must be eliminated on consolidation under Ind AS 110 read with Ind AS 24. Groups that eliminate only the intra-group sale-and-purchase entries but not the profit-in-inventory over-state consolidated gross profit for the year to the extent of the un-eliminated intra-group profit. Discipline: the year-end pack includes a closing-inventory extract per molecule at the formulation plant, a per-molecule intra-group profit-per-kilogram lookup, and the elimination entry driven off the product of the two.
How a reconciliation platform handles this
A purpose-built pharma reconciliation platform ingests the API plant’s GSTR-1 outward supply register, the formulation plant’s GSTR-2B auto-populated ITC statement, the group’s cost accounting records, and the plant master with tax-holiday flags — and produces a per-molecule per-FY intra-group transfer pricing workbook. The Section 92BA SDT threshold monitor cumulates aggregate intra-group SDT against the Rs 20 crore trigger as the year progresses, so the Rule 10D documentation build starts well before the year-end scramble. The API plant dispatch register and the formulation plant receipt register reconcile invoice-by-invoice with a matched pair for each intra-group tax invoice — closing the ITC continuity from the API plant to the formulation plant. The income-tax arm’s length price and the GST invoice value are held as the same number at invoice generation so the second-proviso-to-Rule-28 safe harbour holds. The year-end pack drafts Form 3CEB Part C for accountant certification, exports the Rule 10D contemporaneous documentation set, and prepares the group-consolidation elimination worksheet for intra-group profit-in-inventory. Match rate improvement of 51 to 88 percent on the API-plant-to-formulation-plant intra-group invoice reconciliation, combined with an ISO 27001:2022 posture and DPDP Act 2023 aligned data handling, is what makes the platform an infrastructure investment for a Tier-1 backward-integrated pharma group rather than a spreadsheet substitute.
Cross-cluster bridges and where to read next
The backward-integration transfer pricing reconciliation documented in this article sits alongside the Wave A cornerstone API vs formulation HSN 2941, 3003, 3004 reconciliation guide, which unpacks the Chapter 29 versus Chapter 30 HSN classification logic that the intra-group SDT sits on top of. The Wave B sibling on API import under the Customs Tariff Act 1975 covers the BCD-plus-AIDC-plus-IGST reconciliation for API imports from Zhejiang, Jiangsu or Shandong in China, from Italy, or from the US that flow into the same downstream formulation plant. The API contract manufacturing margin reconciliation for CDMO and CRAMS walkthrough covers the arm’s length margin for third-party contract-manufacturing relationships — the same TNMM mechanic applied to a different counterparty type.
The GST-side reconciliation surface for the formulation plant’s downstream inverted-duty refund cycle — where the intra-group API purchase at 5 percent IGST feeds the Chapter 30 formulation Net ITC — sits in the Wave A cornerstone on Rule 89(5) inverted duty refund for pharma formulations and the Wave B sibling walkthroughs on the Section 54(3) CGST RFD-01 monthly filing workflow and the Notification 14/2022 Net ITC formula amendment.
The methodology framework for building the per-molecule per-FY reconciliation workbook — mapping every intra-group SDT to a distinct reconciliation surface, holding both income-tax and GST-side positions, and building the deficiency-response cycle into the standing close process — sits in Terra Insight’s own reconciliation failure mode analysis pillar and the reconciliation playbook for monthly close operations pillar. The GSTR-2B ITC reconciliation reference — feeding directly into the formulation plant’s ITC availment side of the intra-group transfer — sits at GSTR-2B ITC reconciliation failure modes. The commercial pillar for the pharma sub-cluster is Pharma reconciliation software India; the broader authority for the platform is reconciliation software India with the specialised GST reconciliation software surface for the Section 54(3) refund workflow and the TDS reconciliation software surface for the parallel Section 194Q and Section 206C(1H) TDS-TCS reconciliation on intra-group purchases.
The five FAQs below address the operational questions Indian pharma indirect-tax and transfer-pricing leads ask most often when building the backward-integration API-to-formulation intra-group transfer workbook under Section 92BA.
Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
- ▸ Section 92BA, Income-tax Act 1961 (retained in the Income-tax Act 2025 codification) — Meaning of specified domestic transaction. Includes transactions referred to in Section 80A (inter-unit transfers at tax-holiday units), any transfer of goods or services referred to in sub-section (8) of Section 80-IA (transactions with the tax-holiday unit), any business transacted between the assessee and other person as referred to in sub-section (10) of Section 80-IA, any transaction under Chapter VI-A or Section 10AA (SEZ units) to which sub-section (8) or (10) of Section 80-IA applies (this brings in Section 80-IE and Section 80-IC tax-holiday units), and transactions referred to in sub-section (6) of Section 115BAB (new manufacturing companies at the concessional 15 percent tax rate). The transactions are treated as SDT where the aggregate of such transactions entered into by the assessee in the previous year exceeds a sum of twenty crore rupees. Clause (i) of Section 92BA relating to Section 40A(2)(b) related-party transactions was deleted by the Finance Act 2017 and does not apply.
- ▸ Rule 10D, Income-tax Rules 1962 — Information and documents to be kept and maintained under Section 92D by every person entering into an international transaction or a specified domestic transaction. Prescribes the contemporaneous documentation set — ownership structure of the assessee, profile of the multinational or domestic group, description of the SDT with each associated enterprise, functions performed, risks assumed and assets employed (FAR analysis), transfer pricing methodology selected with reasons, arm's length range benchmarking study drawn from external comparables, and record of economic and market analyses. The documentation must be contemporaneous with the transaction and preserved for eight years from the end of the relevant assessment year.
- ▸ Section 92C read with Rule 10B and Rule 10CA, Income-tax Rules 1962 — Computation of arm's length price under six prescribed methods — Comparable Uncontrolled Price (CUP), Resale Price Method (RPM), Cost Plus Method (CPM), Profit Split Method (PSM), Transactional Net Margin Method (TNMM), and Other Method (as prescribed by the Board). For a proprietary or specialty API where external comparable transactions are limited, TNMM is the pragmatic choice; where an external market price for the same molecule at the same volume tier and delivery terms is verifiable, CUP is the preferred method. Rule 10B(1) prescribes the mechanics of each method; Rule 10CA prescribes the arm's length range computation with the interquartile-range test where six or more comparables are available and the arithmetic-mean plus-or-minus-three-percent-tolerance test in other cases.
- ▸ Form 3CEB, Income-tax Rules 1962 read with Section 92E — Report from an accountant to be furnished under Section 92E in respect of international transactions and specified domestic transactions. Must be filed by 31 October of the assessment year (extended in some years by CBDT notification) as an attachment to the income-tax return. Contains Part C particulars of each SDT — description of the transaction, associated enterprise name and relationship, quantum, transfer pricing method applied, arm's length price computation and comparability adjustments — certified by a chartered accountant. Failure to file attracts a penalty of Rs 1 lakh under Section 271BA; failure to maintain Rule 10D documentation attracts a 2 percent penalty on SDT value under Section 271AA.
- ▸ Section 15 read with Rule 28, Central Goods and Services Tax Act 2017 and Rules 2017 — Value of supply of goods or services between related persons (Section 15(4)) is determined under Rule 28 of the CGST Rules 2017. Rule 28(a) prescribes the open market value as the primary anchor; Rule 28(b) prescribes the value of like kind and quality supplies where OMV is unavailable; failing which Rule 30 (cost of the supply plus 10 percent) or Rule 31 (any other reasonable means consistent with the principles of Section 15) applies. The second proviso to Rule 28 provides a safe harbour: where the recipient is eligible for full input tax credit, the value declared in the invoice by the supplier is deemed to be the open market value. Every intra-group inter-state pharma API transfer from an API plant GSTIN to a formulation plant GSTIN of the same legal entity or of a related group entity is a related-party supply within scope of this rule.
- ▸ Schedule I paragraph 2, Central Goods and Services Tax Act 2017 — Activities to be treated as supply of goods or services even if made without consideration. Paragraph 2 includes supply of goods or services between related persons or between distinct persons (branches or units of the same legal entity registered in different states) when made in the course or furtherance of business. An intra-group inter-state stock transfer of Chapter 29 API from a Maharashtra API plant GSTIN to a Goa formulation plant GSTIN of the same legal entity is a Schedule I paragraph 2 supply and attracts IGST at 5 percent (Chapter 29 heading 2941 for antibiotics) on the Rule 28 value even in the absence of monetary consideration.